FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma

TARRYTOWN, N.Y. and PARIS, April 30, 2018 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologic... Biopharmaceuticals, Oncology, FDA Regeneron Pharmaceuticals, Sanofi, cemiplimab, squamous cell carcinoma

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2043797

Source: HSMN NewsFeed - April 30, 2018 Category: Pharmaceuticals Source Type: news